---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-018639"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:00:22.128011+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics completes 1:18 reverse stock split, reducing shares to ~3.25M

## Summary
- 1:18 reverse stock split effective Feb 10, 2023; shares outstanding drop from 58.5M to ~3.25M.
- Board approved final ratio on Feb 8; stockholders authorized range 1:10–1:25 at Jan 12 special meeting.
- No fractional shares issued; cash payments in lieu. Trading on split-adjusted basis begins Feb 13, 2023.
- CUSIP changes to 92941V 308; all stock options and warrants adjusted proportionally with higher exercise price.

## SEC filing metadata
- accession: 0001104659-23-018639
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/0001104659-23-018639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/tm236109d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-018639
- JSON: https://secwatch.observer/filing/0001104659-23-018639.json
- Plain text: https://secwatch.observer/filing/0001104659-23-018639.txt

## Key facts
- Governance Changes
  VYNE Therapeutics Inc.: Effected a one-for-eighteen reverse stock split of common stock via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-10).
  - Change: charter amendment
  - Effective: 2023-02-10
  source text: On February 10, 2023, VYNE Therapeutics Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a one-for-eighteen (1:18) reverse stock split of its outstanding common stock, effective as of February 10, 2023 (the “Reverse Stock Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/0001104659-23-018639-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.